AAPL345.16+1.17 (+0.34%) ▲|ABBV283.70-1.11 (-0.39%) ▼|ABT102.40+1.89 (+1.88%) ▲|ACN250.63+10.37 (+4.32%) ▲|ADBE270.41+15.35 (+6.02%) ▲|AMAT382.87-26.07 (-6.38%) ▼|AMD515.87-36.85 (-6.67%) ▼|AMGN448.50+10.16 (+2.32%) ▲|AMT181.12+3.48 (+1.96%) ▲|AMZN252.83-9.54 (-3.64%) ▼|AVGO325.60-12.21 (-3.61%) ▼|AXP323.72+0.11 (+0.03%) ▲|BA189.87-2.41 (-1.25%) ▼|BAC50.94+0.16 (+0.31%) ▲|BKNG162.10+3.72 (+2.35%) ▲|BLK1,141.03-8.57 (-0.75%) ▼|BMY62.79+1.67 (+2.73%) ▲|BNY144.18-1.67 (-1.15%) ▼|BRK-B548.48+9.49 (+1.76%) ▲|C122.15-1.71 (-1.38%) ▼|CAT705.10-35.12 (-4.74%) ▼|CL96.83+3.43 (+3.67%) ▲|CMCSA22.88+0.80 (+3.62%) ▲|COF204.44-2.23 (-1.08%) ▼|COP144.88-0.79 (-0.54%) ▼|COST1,009.82+11.51 (+1.15%) ▲|CRM249.25+7.47 (+3.09%) ▲|CSCO104.56-2.71 (-2.52%) ▼|CVS93.99+1.21 (+1.30%) ▲|CVX224.37-2.41 (-1.06%) ▼|DE638.30+1.76 (+0.28%) ▲|DHR232.42-1.45 (-0.62%) ▼|DIS113.00+1.17 (+1.05%) ▲|DUK123.57+2.90 (+2.40%) ▲|EMR158.15-4.96 (-3.04%) ▼|FDX301.75+3.52 (+1.18%) ▲|GD346.66+1.95 (+0.57%) ▲|GE291.48-4.40 (-1.49%) ▼|GEV829.29-96.63 (-10.44%) ▼|GILD155.79+2.22 (+1.45%) ▲|GM76.95+0.84 (+1.10%) ▲|GOOG323.64-7.31 (-2.21%) ▼|GOOGL327.55-7.21 (-2.15%) ▼|GS891.71-13.01 (-1.44%) ▼|HD324.76+10.62 (+3.38%) ▲|HON215.50+0.77 (+0.36%) ▲|IBM249.07-2.40 (-0.95%) ▼|INTC87.75-5.21 (-5.60%) ▼|INTU355.65+20.04 (+5.97%) ▲|ISRG439.80+11.68 (+2.73%) ▲|JNJ266.77+8.99 (+3.49%) ▲|JPM334.54-0.65 (-0.19%) ▼|KO94.65+1.97 (+2.13%) ▲|LIN509.18+8.61 (+1.72%) ▲|LLY1,313.27+42.52 (+3.35%) ▲|LMT582.25+30.74 (+5.57%) ▲|LOW203.69+7.13 (+3.62%) ▲|LRCX235.46-25.35 (-9.72%) ▼|MA631.93+9.31 (+1.49%) ▲|MCD250.60+4.35 (+1.77%) ▲|MDLZ64.33+1.59 (+2.53%) ▲|MDT95.78+2.75 (+2.96%) ▲|META654.00-43.52 (-6.24%) ▼|MMM174.01-0.73 (-0.42%) ▼|MO75.39+1.56 (+2.11%) ▲|MRK152.09+2.21 (+1.47%) ▲|MS183.81-3.20 (-1.71%) ▼|MSFT526.09-6.86 (-1.29%) ▼|MU870.16-43.52 (-4.76%) ▼|NEE80.74+2.46 (+3.14%) ▲|NFLX67.23+2.19 (+3.36%) ▲|NKE38.25+0.72 (+1.92%) ▲|NOW156.61+3.49 (+2.28%) ▲|NVDA213.86-8.12 (-3.66%) ▼|ORCL126.23-2.90 (-2.25%) ▼|PEP137.97+3.27 (+2.43%) ▲|PFE30.27+0.42 (+1.39%) ▲|PG166.03+9.19 (+5.86%) ▲|PLTR199.03-2.69 (-1.33%) ▼|PM200.96+3.50 (+1.77%) ▲|QCOM175.40-2.57 (-1.44%) ▼|RTX191.82+0.22 (+0.11%) ▲|SBUX101.53+2.45 (+2.47%) ▲|SCHW92.34+0.70 (+0.76%) ▲|SO92.79+2.40 (+2.66%) ▲|SPG210.17+4.62 (+2.25%) ▲|T22.53+0.62 (+2.81%) ▲|TMO683.47-10.55 (-1.52%) ▼|TMUS157.52+3.77 (+2.45%) ▲|TSLA381.59-4.89 (-1.26%) ▼|TXN282.10-2.56 (-0.90%) ▼|UBER68.58+0.96 (+1.41%) ▲|UNH425.88+8.88 (+2.13%) ▲|UNP295.77+7.90 (+2.74%) ▲|UPS101.25+1.68 (+1.69%) ▲|USB59.89+0.84 (+1.41%) ▲|V414.18+6.33 (+1.55%) ▲|VZ44.59+1.03 (+2.36%) ▲|WFC83.08+0.66 (+0.80%) ▲|WMT120.13+2.33 (+1.98%) ▲|XOM176.13-1.97 (-1.10%) ▼|AAPL345.16+1.17 (+0.34%) ▲|ABBV283.70-1.11 (-0.39%) ▼|ABT102.40+1.89 (+1.88%) ▲|ACN250.63+10.37 (+4.32%) ▲|ADBE270.41+15.35 (+6.02%) ▲|AMAT382.87-26.07 (-6.38%) ▼|AMD515.87-36.85 (-6.67%) ▼|AMGN448.50+10.16 (+2.32%) ▲|AMT181.12+3.48 (+1.96%) ▲|AMZN252.83-9.54 (-3.64%) ▼|AVGO325.60-12.21 (-3.61%) ▼|AXP323.72+0.11 (+0.03%) ▲|BA189.87-2.41 (-1.25%) ▼|BAC50.94+0.16 (+0.31%) ▲|BKNG162.10+3.72 (+2.35%) ▲|BLK1,141.03-8.57 (-0.75%) ▼|BMY62.79+1.67 (+2.73%) ▲|BNY144.18-1.67 (-1.15%) ▼|BRK-B548.48+9.49 (+1.76%) ▲|C122.15-1.71 (-1.38%) ▼|CAT705.10-35.12 (-4.74%) ▼|CL96.83+3.43 (+3.67%) ▲|CMCSA22.88+0.80 (+3.62%) ▲|COF204.44-2.23 (-1.08%) ▼|COP144.88-0.79 (-0.54%) ▼|COST1,009.82+11.51 (+1.15%) ▲|CRM249.25+7.47 (+3.09%) ▲|CSCO104.56-2.71 (-2.52%) ▼|CVS93.99+1.21 (+1.30%) ▲|CVX224.37-2.41 (-1.06%) ▼|DE638.30+1.76 (+0.28%) ▲|DHR232.42-1.45 (-0.62%) ▼|DIS113.00+1.17 (+1.05%) ▲|DUK123.57+2.90 (+2.40%) ▲|EMR158.15-4.96 (-3.04%) ▼|FDX301.75+3.52 (+1.18%) ▲|GD346.66+1.95 (+0.57%) ▲|GE291.48-4.40 (-1.49%) ▼|GEV829.29-96.63 (-10.44%) ▼|GILD155.79+2.22 (+1.45%) ▲|GM76.95+0.84 (+1.10%) ▲|GOOG323.64-7.31 (-2.21%) ▼|GOOGL327.55-7.21 (-2.15%) ▼|GS891.71-13.01 (-1.44%) ▼|HD324.76+10.62 (+3.38%) ▲|HON215.50+0.77 (+0.36%) ▲|IBM249.07-2.40 (-0.95%) ▼|INTC87.75-5.21 (-5.60%) ▼|INTU355.65+20.04 (+5.97%) ▲|ISRG439.80+11.68 (+2.73%) ▲|JNJ266.77+8.99 (+3.49%) ▲|JPM334.54-0.65 (-0.19%) ▼|KO94.65+1.97 (+2.13%) ▲|LIN509.18+8.61 (+1.72%) ▲|LLY1,313.27+42.52 (+3.35%) ▲|LMT582.25+30.74 (+5.57%) ▲|LOW203.69+7.13 (+3.62%) ▲|LRCX235.46-25.35 (-9.72%) ▼|MA631.93+9.31 (+1.49%) ▲|MCD250.60+4.35 (+1.77%) ▲|MDLZ64.33+1.59 (+2.53%) ▲|MDT95.78+2.75 (+2.96%) ▲|META654.00-43.52 (-6.24%) ▼|MMM174.01-0.73 (-0.42%) ▼|MO75.39+1.56 (+2.11%) ▲|MRK152.09+2.21 (+1.47%) ▲|MS183.81-3.20 (-1.71%) ▼|MSFT526.09-6.86 (-1.29%) ▼|MU870.16-43.52 (-4.76%) ▼|NEE80.74+2.46 (+3.14%) ▲|NFLX67.23+2.19 (+3.36%) ▲|NKE38.25+0.72 (+1.92%) ▲|NOW156.61+3.49 (+2.28%) ▲|NVDA213.86-8.12 (-3.66%) ▼|ORCL126.23-2.90 (-2.25%) ▼|PEP137.97+3.27 (+2.43%) ▲|PFE30.27+0.42 (+1.39%) ▲|PG166.03+9.19 (+5.86%) ▲|PLTR199.03-2.69 (-1.33%) ▼|PM200.96+3.50 (+1.77%) ▲|QCOM175.40-2.57 (-1.44%) ▼|RTX191.82+0.22 (+0.11%) ▲|SBUX101.53+2.45 (+2.47%) ▲|SCHW92.34+0.70 (+0.76%) ▲|SO92.79+2.40 (+2.66%) ▲|SPG210.17+4.62 (+2.25%) ▲|T22.53+0.62 (+2.81%) ▲|TMO683.47-10.55 (-1.52%) ▼|TMUS157.52+3.77 (+2.45%) ▲|TSLA381.59-4.89 (-1.26%) ▼|TXN282.10-2.56 (-0.90%) ▼|UBER68.58+0.96 (+1.41%) ▲|UNH425.88+8.88 (+2.13%) ▲|UNP295.77+7.90 (+2.74%) ▲|UPS101.25+1.68 (+1.69%) ▲|USB59.89+0.84 (+1.41%) ▲|V414.18+6.33 (+1.55%) ▲|VZ44.59+1.03 (+2.36%) ▲|WFC83.08+0.66 (+0.80%) ▲|WMT120.13+2.33 (+1.98%) ▲|XOM176.13-1.97 (-1.10%) ▼|
16.1 C
New York
Thursday, October 22, 2026

Tag: therapies

newsFORsourcecompanycontentinformation1releasesmarket

Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease

Atrogi's breakthrough discovery enables chronic use of next-generation, highly selective β2-agonists for the first time in metabolic diseaseFirst-in-class oral therapy ATR-258 mimics the effects...

Atrogi announces Cell paper highlighting transformative potential of muscle-targeted therapy in metabolic disease

Atrogi's breakthrough discovery enables chronic use of next-generation, highly selective β2-agonists for the first time in metabolic diseaseFirst-in-class oral therapy ATR-258 mimics the effects...

Sana Biotechnology Announces Positive Six-Month Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

Groundbreaking First-in-Human Study Establishes Potential to Treat Type 1 Diabetes by Transplanting Insulin-Secreting Cells Without Immunosuppression

Nipocalimab showed greater sustained disease control versus approved FcRn blockers for generalised myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly published...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control in managing a chronic autoantibody disease like gMG

IMAAVY™ (nipocalimab-aahu) showed greater sustained disease control versus approved FcRn blockers for generalized myasthenia gravis (gMG) at multiple timepoints over 24 weeks in newly...

The ITC compared all published Phase 3 data of these treatments, leveraging longitudinal results, and findings reinforce the importance of consistent, sustained disease control...

Cell Study by SDU and PKU Researchers Reveals Novel Mechanism to Regulate Glucose Metabolism

JINAN, China, June 23, 2025 /PRNewswire/ -- On May 29, 2025, Professor Sun Jinpeng's team and Professor Yu Xiao's team at Shandong University, collaborating with Professor...

Cell Study by SDU and PKU Researchers Reveals Novel Mechanism to Regulate Glucose Metabolism

JINAN, China, June 23, 2025 /PRNewswire/ -- On May 29, 2025, Professor Sun Jinpeng's team and Professor Yu Xiao's team at Shandong University, collaborating with Professor...

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent for Clear Cell Renal...


Garching / Munich, Germany, and Lausanne, Switzerland - June 23, 2025 – ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and Debiopharm, a Swiss-based, global biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced that the first patient was imaged in a new study arm of a five-part, Phase 1/2 clinical trial (formerly GaLuCi™) (NCT05706129) evaluating the theranostic pair ITM-94/ITM-91 for identification and treatment of patients who have unresectable, locally advanced or metastatic solid tumors. As a new component of a broad clinical development plan for ITM-91/ITM-94, Part D of the trial will evaluate the effectiveness of ITM-94 in classifying indeterminate renal mass as either ccRCC or non-cancerous.

Herspiegel Acquires Decisive Consulting to Expand Global Life Sciences Commercialization Services

Blending Bold Strategy with Proven Market Access and Health Economics Expertise to Unlock Asset Value YARDLEY, Pa. and LONDON, June 23, 2025 /PRNewswire/ -- Herspiegel,...

Navamedic ASA expands into addiction treatment through the acquisition of the business of dne pharma and announces a partially underwritten rights issue

NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA, THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE...

New study published in Journal of Experimental Medicine reveals a CARMIL2 mutation with therapeutic antitumor potential

Press Release

IASO Bio presents promising efficacy of Equecabtagene Autoleucel in patients with Multiple Sclerosis in IIT study at the 11th Congress of the European Academy...

SHANGHAI and NANJING, China and SAN FRANCISCO, June 22, 2025 /PRNewswire/ -- IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development,...

XtalPi Announces Strategic Collaboration with Harvard Professor Gregory Verdine’s DoveTree LLC to Advance Novel Therapeutics Using AI+Robotics Drug Discovery Platform

CAMBRIDGE, Mass. , June 23, 2025 /PRNewswire/ -- XtalPi, a global leader in AI- and robotics-powered drug and materials discovery, today announced it has signed...

Harbour BioMed Enters Global Strategic Collaboration with Otsuka to Advance BCMAxCD3 Bispecific T-Cell Engagers

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 22, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development...

- A word from our sponsors -

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsTherapies

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers